FDA Renews and Expands its Use of Certara Software

Published on: 

Applied Clinical Trials

Certara, a provider of drug development, regulatory science, market access, and real-world evidence solutions, announced that the US Food and Drug Administration has renewed its number of Certara software licenses such as Certara Phoenix, Simcyp, and Synchrogenix GlobalSubmit,  for reviewing new drug and biologics applications.   Read the full release here.